Extended access to ZVS101e for BCD patients
Part of Eyes & vision clinical trials.
This trial offers compassionate use of the gene therapy ZVS101e for people with Bietti crystalline dystrophy (BCD) who were in the control group of an earlier study. It aims to give extended treatment access to those who didn't receive the experimental therapy before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were part of the control group in a previous ZVS101e study and finished the 52-week checkup.
- Your study eye must have a vision score of 60 letters or worse on the ETDRS eye chart (about 20/60 or worse).
- You must not have other serious eye problems like macular holes, glaucoma, or diabetic retinopathy in the study eye.
- You cannot have had gene therapy, stem cell therapy, or certain eye surgeries in the past.
- You must be willing to sign a consent form and follow all study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for Bietti's crystalline dystrophy, a rare inherited eye disease that causes progressive vision loss. The treatment aims to slow or stop vision loss by delivering a healthy gene to the eye.
This study tests the safety of giving the same gene therapy to your second eye, after you already received it in one eye during an earlier study. It aims to see if it's safe and may help improve vision.
This trial tests a new gene therapy called ZVS106e for people with inherited retinal degeneration caused by changes in both copies of the ABCA4 gene. The therapy aims to slow or stop vision loss, and the study will check if it is safe and if it works.
This trial tests a new gene therapy called ZVS203e for people with retinitis pigmentosa caused by a specific RHO gene mutation. It aims to see if the treatment is safe and can help improve vision.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This trial tests an injection called PUMCH-E101 for people with vision loss caused by changes in the RDH12 gene. The goal is to see if it is safe and if it can help improve vision.
Hear when a new Bietti Crystalline Corneoretinal Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.